- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.11. | Acrivon Therapeutics stock rating reiterated by Citizens with $13 target | 1 | Investing.com | ||
| 17.11. | Acrivon Therapeutics: Citizens bestätigt Rating "Market Outperform" und Kursziel von 13 US-Dollar | 2 | Investing.com Deutsch | ||
| 13.11. | Acrivon Therapeutics GAAP EPS of -$0.47 beats by $0.12 | 1 | Seeking Alpha | ||
| 13.11. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights | 87 | GlobeNewswire (Europe) | Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial... ► Artikel lesen | |
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Acrivon Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11. | Acrivon Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10. | Acrivon to present data on AI-driven cancer drug development at conference | 2 | Investing.com | ||
| 01.10. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 99 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing... ► Artikel lesen | |
| 17.09. | Citizens analyst reiterates Market Outperform rating on Acrivon stock | 2 | Investing.com | ||
| 17.09. | Acrivon: Citizens JMP bestätigt "Market Outperform" und Kursziel von 13 US-Dollar | 1 | Investing.com Deutsch | ||
| 05.09. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 13.08. | Acrivon Therapeutics GAAP EPS of -$0.55 | 1 | Seeking Alpha | ||
| 13.08. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | 294 | GlobeNewswire (Europe) | Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and... ► Artikel lesen | |
| 13.08. | Acrivon Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.05. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 644 | GlobeNewswire (Europe) | Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of... ► Artikel lesen | |
| 07.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer | 328 | GlobeNewswire (Europe) | Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of... ► Artikel lesen | |
| 27.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results | 218 | GlobeNewswire (Europe) | Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,85 | +0,06 % | BioNTech: Starke Studiennews - Aktie zieht an | Die Aktie von BioNTech kann zum Wochenstart deutlich zulegen. Gute News vom Wochenende zum Produktkandidaten BNT316 bei Lungenkrebs unterstützen die Aktie. Für einen charttechnischen Befreiungsschlag... ► Artikel lesen | |
| CUREVAC | 4,270 | -0,84 % | Wochenend-Update: Curevac-Aktie im Fokus - was Anleger jetzt wissen müssen! | ||
| AMGEN | 268,60 | -0,79 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,602 | +0,02 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 148,20 | -0,10 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| MAINZ BIOMED | 1,040 | -0,95 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,110 | +1,73 % | Viking Therapeutics-Aktie: Was kommt 2026? | Kurz vor Jahresende nehmen wir die Aktie von Viking Therapeutics noch einmal unter die Lupe, denn das Unternehmen steht vor einem entscheidenden Jahr für seine Adipositas-Pipeline. Zwar sind keine Zulassungsentscheidungen... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,800 | +1,46 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 59,50 | -1,65 % | Tempus AI's Strategic Push to Expand Beyond Oncology | ||
| BIOCRYST PHARMACEUTICALS | 6,274 | -2,79 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,340 | -0,03 % | Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing | ||
| BIOMARIN PHARMACEUTICAL | 45,000 | -0,88 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| EXELIXIS | 35,150 | +0,98 % | Exelixis stock holds steady as Stifel maintains $43 price target | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,855 | +2,50 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,911 | +1,56 % | Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions | Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with... ► Artikel lesen |
ACRIVON THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,080 (-3,07 %) liegt der Kurs bei 2,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.